TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Public ClinicalTrials.gov record NCT05980598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Study identification
- NCT ID
- NCT05980598
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- TransCon IL-2 β/γ Drug
- TransCon TLR7/8 Agonist Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2023
- Primary completion
- Mar 27, 2025
- Completion
- Mar 27, 2025
- Last update posted
- Jul 31, 2025
2023 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Investigational Site | Los Angeles | California | 90067 | — |
| Ascendis Investigational Site | San Francisco | California | 94158 | — |
| Ascendis Investigational Site | Chicago | Illinois | 60612 | — |
| Ascendis Investigational Site | Springfield | Illinois | 62702 | — |
| Ascendis Investigational Site | Iowa City | Iowa | 52242 | — |
| Ascendis Investigational Site | Louisville | Kentucky | 40202 | — |
| Ascendis Investigational Site | Boston | Massachusetts | 02114 | — |
| Ascendis Investigational Site | Detroit | Michigan | 48201 | — |
| Ascendis Investigational Site | Rochester | Minnesota | 55905 | — |
| Ascendis Investigational Site | New York | New York | 11794 | — |
| Ascendis Pharma Investigational Site | Canton | Ohio | 44718 | — |
| Ascendis Investigational Site | Cincinnati | Ohio | 45219 | — |
| Ascendis Investigational Site | Columbus | Ohio | 43210 | — |
| Ascendis Investigational Site | Charleston | South Carolina | 29425 | — |
| Ascendis Investigational Site | Knoxville | Tennessee | 37902 | — |
| Ascendis Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05980598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05980598 live on ClinicalTrials.gov.